Quinn Opportunity Partners LLC Boosts Holdings in Medifast Inc $MED

Quinn Opportunity Partners LLC increased its holdings in Medifast Inc (NYSE:MED) by 4.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 127,112 shares of the specialty retailer’s stock after purchasing an additional 4,940 shares during the quarter. Quinn Opportunity Partners LLC owned 1.16% of Medifast worth $1,786,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. grew its position in Medifast by 132.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 265,572 shares of the specialty retailer’s stock worth $3,580,000 after acquiring an additional 151,434 shares during the last quarter. CWM LLC increased its position in shares of Medifast by 564.6% in the second quarter. CWM LLC now owns 7,457 shares of the specialty retailer’s stock valued at $105,000 after acquiring an additional 6,335 shares during the period. Allianz Asset Management GmbH bought a new position in shares of Medifast during the second quarter valued at about $307,000. Acadian Asset Management LLC boosted its holdings in shares of Medifast by 41.5% during the first quarter. Acadian Asset Management LLC now owns 385,723 shares of the specialty retailer’s stock worth $5,193,000 after purchasing an additional 113,111 shares during the period. Finally, Nuveen LLC purchased a new position in Medifast during the 1st quarter valued at about $407,000. 95.51% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wall Street Zen cut Medifast from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Medifast in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $16.50.

Medifast Price Performance

NYSE:MED opened at $11.64 on Wednesday. The firm’s 50-day moving average price is $13.26 and its 200-day moving average price is $13.53. The company has a market capitalization of $127.94 million, a PE ratio of 36.38 and a beta of 0.82. Medifast Inc has a 1-year low of $11.25 and a 1-year high of $21.98.

Medifast (NYSE:MED) last posted its quarterly earnings data on Monday, November 3rd. The specialty retailer reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.20). Medifast had a return on equity of 2.00% and a net margin of 0.76%.The business had revenue of $89.41 million for the quarter, compared to the consensus estimate of $84.10 million. Medifast has set its Q4 2025 guidance at -1.250–0.70 EPS. Equities analysts anticipate that Medifast Inc will post 0.51 EPS for the current fiscal year.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.